Drug Approval | June 26, 2026
FDA expands Pfizer’s IBRANCE use in HER2-positive breast cancer
Backed by Phase 3 trial showing 24% lower risk of progression
Backed by Phase 3 trial showing 24% lower risk of progression
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
Company secures 7th position nationwide in India's Great Mid-size Workplaces 2026, reinforcing its people-first culture as it marks 75 years of excellence
Partnership with Sunshine Healthcare aims to build local pharmaceutical capabilities and strengthen supply chain resilience
Experts announce upcoming Amyotrophic lateral sclerosis (ALS) studies, advocate early diagnosis, comprehensive care, and stronger support systems for patients and caregivers
Acquisition strengthens Merck's life sciences portfolio, expands capabilities across research and biopharma manufacturing
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
National conference brings together 160+ experts from six states to advance blood quality and safety standards
Partnership with MAMTA HIMC aims to boost awareness, screening, HPV vaccination, and early detection of breast and cervical cancer in underserved communities
The company plans to use this funding to boost AI capabilities, expand vernacular content ecosystem, accelerate product development, and scale user acquisition across Tier 2 and Tier 3 markets
Subscribe To Our Newsletter & Stay Updated
